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Purpose: Weekly paclitaxel combined with a
platinum-based agent has been advocated as an alter-
native regimen for patients with advanced non–small
cell lung cancer (NSCLC). Limited studies exist on the
tolerability of weekly paclitaxel in Japanese patients
with advanced NSCLC. Furthermore, the feasibility of
dexamethasone taper in the premedication regimen
for weekly paclitaxel has not been examined in these
patients. To address this issue, we assessed the
maximum tolerated dose, dose-limiting toxicity, and
pharmacokinetics of weekly paclitaxel in Japanese
patients with advanced NSCLC in a dose-escalation
Phase I trial and examined the feasibility of dexame-
thasone taper in these patients.
Methods: Weekly 1-hour infusions of paclitaxel
were administered at doses of 80 to 120 mg/m2 (dose
escalation of 20 mg/m2). The 7-week treatment cycle
consisted of 6 infusions followed by a 2-week treat-
ment interval. Pharmacokinetics were assessed during
the ﬁrst cycle. Dexamethasone was commenced at 16
mg and doses were successively halved if hypersensi-
tivity reactions were absent.
Findings: A total of 15 patients with either Stage IIIB
or IV NSCLC were enrolled. Although no dose-limiting
toxicity was observed at 120 mg/m2, 4 of 6 patients
with peripheral neuropathy required discontinuation of
treatment. The maximum accepted dose and the
recommended dose were 120 and 100 mg/m2, respec-
tively. No grade Z3 adverse events were observed at
100 mg/m2. The maximum drug concentration and
AUC correlated with dose escalation. The pharmaco-
kinetic parameters after the ﬁrst and sixth infusions
were similar, indicating that repeated administration of*M. Hiraoka has retired from Bristol-Myers K.K.
338paclitaxel did not result in drug accumulation or affect
its pharmacokinetic proﬁle. Partial response was ob-
served in 3 of 15 patients. Plasma adrenocorticotropic
hormone and cortisol levels decreased during treatment
but approached baseline levels after a dexamethasone-
free interval.
Implications:Weekly paclitaxel at 100 mg/m2 given
as a 1-hour infusion for 6 weeks followed by a 2-week
treatment interval was well tolerated by Japanese
patients with advanced NSCLC. Dexamethasone
taper was feasible in these patients, and no clear
trend in plasma adrenocorticotropic hormone or corti-
sol levels was observed. (Clin Ther. 2016;38:338–347)
& 2016 The Authors. Published by Elsevier HS Jour-
nals, Inc.
Key words: dexamethasone, paclitaxel, pharmaco-
kinetics, phase I, safety.INTRODUCTION
The efﬁcacy of paclitaxel in platinum-doublet regi-
mens administered every 3 weeks as ﬁrst-line treat-
ment for advanced non–small cell lung cancer
(NSCLC) is fully established.1–5 Apart from the stand-
ard 3-weekly regimen, weekly paclitaxel combined
with a platinum-based agent has been advocated as an
alternative regimen for patients with advanced
NSCLC.6–9 This is based on the concept of dose-
dense therapy, in which paclitaxel is administered at a
relatively low dose but with more frequent (weekly)& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dose-dense therapy enables maintenance of therapeu-
tic blood concentrations, thereby preventing the de-
velopment of resistant tumor clones and tumor
regrowth that potentially arise in the treatment-free
intervals. Weekly paclitaxel has been demonstrated to
be superior to standard 3-weekly regimens in ad-
vanced ovarian cancer10 and metastatic breast
cancer11 and as adjuvant therapy for breast can-
cer.12 In advanced NSCLC, similar efﬁcacy was
observed between weekly and 3-weekly paclitaxel
regimens, but the former was associated with a
signiﬁcantly lower prevalence of arthralgia and grades
2 and 3 neuropathy.9 Furthermore, weekly paclitaxel,
either as combined or monotherapy, has been
considered an active and feasible option in elderly
patients in Phase II trials.13,14 Limited studies exist on
weekly paclitaxel in Japanese patients with advanced
NSCLC.13,15,16
Despite premedication with dexamethasone and
H1/H2 blockers, severe hypersensitivity reactions occur
in 2% to 4% of patients receiving 3-weekly paclitaxel.17
The standard premedication regimen is 20 mg of
dexamethasone administered at 12 and 6 hours before
paclitaxel infusions. This regimen repeatedly exposes
patients to a potent, high-dose corticosteroid, partic-
ularly for those receiving weekly paclitaxel. Hypoth-
alamic-pituitary-adrenal axis suppression is possible
after prolonged dexamethasone administration, and
abrupt cessation may cause adrenal insufﬁciency, altho-
ugh the risk for this in paclitaxel premedication regi-
mens is unknown. To decrease the likelihood of
dexamethasone-related adverse effects, attempts have
been made to reduce the cumulative dose by reducing
individual doses,18 reducing frequency of administ-
ration,19–24 tapering25,26 or omission after uneventful
completion of the ﬁrst 1 or 2 paclitaxel doses.17,27 The
prevalence of hypersensitivity reactions after dexame-
thasone dose reduction in weekly paclitaxel regimens
was comparable to that in those using routine premed-
ication.17,21,27 To our knowledge, no studies exist that
have examined the feasibility of dexamethasone taper in
Japanese NSCLC patients receiving weekly paclitaxel.
Furthermore, there is little information about changes in
adrenocortical function in patients receiving weekly
dexamethasone as premedication for a weekly pacli-
taxel regimen.
The aims of the present study were to examine the
pharmacokinetics, dose-limiting toxicity (DLT), andFebruary 2016maximum tolerated dose (MTD) of weekly paclitaxel
in Japanese patients with advanced NSCLC and to
examine the feasibility of dexamethasone taper in the
premedication regimen. The secondary objective was
to investigate the effect of dexamethasone on adreno-
cortical function in Japanese NSCLC patients by
analyzing plasma ACTH and serum/urinary cortisol
levels.PATIENTS AND METHODS
Patient Recruitment
The study was approved by the institutional review
board of the National Cancer Center, Tokyo, Japan.
All patients provided written informed consent before
enrollment in the study. Patients were eligible for the
study if they met the following inclusion criteria: (1) a
histologically or cytologically proven diagnosis of
NSCLC; (2) age between 20 and r75 years; (3) an
Eastern Cooperative Oncology Group Performance
Status of 0 or 1; (4) an interval of at least 4 weeks
since completion of prior treatment for NSCLC, and
an interval of at least 2 weeks since completion of
treatment with biological response modiﬁers, adjuvant
therapy, or radiotherapy limited to the brain or bones;
(5) a life expectancy of at least 2 months from the
start of treatment; (6) ability to receive at least one
treatment cycle as an inpatient; and (7) adequate
organ function. The exclusion criteria were as follows:
(1) history of paclitaxel therapy; (2) poorly controlled
diabetes mellitus or presence of serious complications
of diabetes; (3) history of serious hypersensitivity
reaction or anaphylaxis; (4) history of hypersensitivity
to preparations containing polyoxyethylene castor oil
or hydrogenated castor oil; (5) presence of peripheral
neuropathy grade Z1 (National Cancer Institute
Common Terminology Criteria for Adverse Events
version 2.0); (6) presence of an acute inﬂammatory
disease; (7) pregnancy or breastfeeding in women; and
(8) patients for whom supportive therapy, such as life-
saving blood transfusions for myelosuppression, was
not possible.
Premedication and Paclitaxel Administration
Dexamethasone at varying doses (1–16 mg IV)
followed by diphenhydramine at 50 mg (oral) and
ranitidine at 50 mg (IV) were given 30 to 60 minutes
before paclitaxel administration. Paclitaxel dissolved
in 250 mL of saline was administered by IV infusion339
Clinical Therapeuticsover a period of 1 hour (within 1.5 hours or less in
principle). One 7-week cycle of treatment consisted of
paclitaxel administered once a week for 6 consecutive
weeks followed by a 2-week treatment-free interval.
Patients received at least 1 cycle of treatment.
Dexamethasone was administered at an initial dose
of 16 mg. In week 2, if there was no hypersensitivity
reaction, it was subsequently administered at 8 mg.
Successive doses were halved in the absence of hyper-
sensitivity reactions to a minimal dose of 2 mg. If a
hypersensitivity reaction occurred at 2 mg, the dose
was increased to 4 mg in the following week of
paclitaxel administration. If the MTD was deter-
mined, the initial dexamethasone dose of 8 mg, which
was to be assessed for lower starting dose, could be
tapered to a minimum of 1 mg in patients receiving
the subsequently determined recommended dose, in
the absence of hypersensitivity reactions.
Paclitaxel was administered at an initial dose of
80 mg/m2 (level 1), and the dose was escalated in
20-mg/m2 increments to a maximum of 160 mg/m2
(level 5). Three patients were enrolled at each dose
level. The next dose level was initiated if DLT was
absent in all 3 patients. If a DLT occurred, 2 or 3
patients were added to the same dose level (3 þ 3
design). If Z2 DLTs occurred in the group with a
total of 5 or 6 patients at a dose level, the advice of the
Data and Safety Monitoring Committee (DSMC) on
the feasibility of a dose escalation was sought. The
MTD was deﬁned as the dose that causedZ2 DLTs in
the original group of 3 patients or Z3 DLTs in the
subsequent group of 5 or 6 patients.
DLTs were deﬁned as the following events: (1)
grade 4 leukopenia or thrombocytopenia; (2) grade 4
neutropenia lasting for Z4 days; (3) grade 3 leuko-
penia or neutropenia associated with a fever Z381C;
(4) grade Z3 nonhematologic toxicities (these were
judged by the DSMC and excluded nausea/vomiting,
anorexia, malaise, and toxicities attributable to the
pathologic condition itself); and (5) toxicity leading
to an omission of study treatment forZ2 weeks of the
6-week administration.
Evaluations of Efficacy and Tolerability
Toxicities were evaluated using National Cancer
Institute Common Terminology Criteria for Adverse
Events version 2.0. All signs and symptoms at baseline
and those that appeared in the period from commence-
ment of the ﬁrst cycle to 2 weeks after completion340of treatment were documented. Tumor response was
evaluated using Response Evaluation Criteria in Solid
Tumors version 1.0.Pharmacokinetic Evaluation
Pharmacokinetic studies were conducted during the
ﬁrst cycle. Blood samples were collected from all patients
immediately before and at 0, 0.5, 1, 2, 4, 7, 24, and 36
hours after infusion at weeks 1 and 6 and predose on
day 15 or 22. The collected plasma was frozen until
examination by HPLC.28 The lower limit of quantitation
of plasma paclitaxel was 0.020 mg/mL. The following
pharmacokinetic parameters were calculated from the
plasma concentration: Cmax; Tmax; AUC0–1 obtained by
linear/log-linear trapezoidal quadrature; AUC0–1
extrapolated by summing last quantiﬁed concentration/
elimination rate constant to AUClast; AUClast; t½ (0.693/
ke); CLtot, total clearance (Dose/AUC0–1); MRT0–1,
mean residence time ([area under the moment curve]/
AUC); accumulation ratio (AUC [week 6]/AUC [week 1]
or Cmax [week 6]/Cmax [week 1]); and Vss, volume of
distribution at steady state (CL MRT). The mean (SD)
of each pharmacokinetic parameter was calculated and
tabulated by dose level and between the ﬁrst and the ﬁnal
infusions in the ﬁrst cycle. For each pharmacokinetic
parameter, ANOVAs were tested between weeks 1 and 6
to identify pharmacokinetic changes during repeated
administration.Measurement of Morning Plasma ACTH and
Serum/Urinary Cortisol
Measurements of plasma adrenocorticotropic hor-
mone (ACTH) and serum/urinary cortisol, as well as
monitoring of adverse events, were conducted to
assess the effect of dexamethasone on adrenocortical
function. Weekly morning plasma ACTH and cortisol
were measured during the ﬁrst cycle of weekly
paclitaxel treatment. Urinary cortisol and 6β-
hydroxycortisol (OHC) in urine collected over 24
hours were measured at week 1 (day 1), week 3
(day 15), week 4 (day 22), and week 6 (day 36) in the
ﬁrst cycle, and before paclitaxel administration (day
50) in the second cycle. Examinations of plasma
ACTH and serum/urinary cortisol were not performed
in the second or subsequent cycles if no clinical
abnormalities were seen during the ﬁrst cycle.
6β-OHC levels were determined only in the ﬁrst cycle.
Mean (SD) urinary 6β-OHC/cortisol (C) ratios wereVolume 38 Number 2
H. Nokihara et al.calculated before the start of paclitaxel infusion in
weeks 1, 3, 4, and 6 of the ﬁrst and second cycles.RESULTS
Patient Characteristics
A total of 15 eligible patients with NSCLC were
enrolled between October 2000 and July 2001, and their
baseline characteristics are shown in Table I. All patients
were male, with a median age of 57 years (range, 49–69
years), and 26.7% and 73.3% had an Eastern
Cooperative Oncology Group Performance Status of 0
and 1, respectively. Of the 15 patients, 6 had prior
surgical treatment, 3 had surgery plus radiotherapy, and
2 had chemotherapy only. Paclitaxel was initially given
to 3, 3, and 6 patients at levels 1 (80 mg/m2), 2 (100
mg/m2), and 3 (120 mg/m2), respectively. An additional
3 patients received paclitaxel at level 2 after obtaining
the results of the level 3 dosing. All patients received at
least 1 treatment cycle (median, 2; range, 1–5).
Toxicity
No grade 4 toxicity was seen and no DLT occurred.
Common toxicities at each respective dose level during
the ﬁrst cycle are listed in Table II. The most common
adverse events were alopecia (93.3%), peripheral
neuropathy (80%), anorexia (60%), fatigue (60%),
and arthralgia (40%) during the ﬁrst cycle. One patient
had grade 1 Cushing syndrome during the fourth cycle
while on 2 mg of dexamethasone. No gradeZ3 clinical
nonhematologic malignancies were observed.Table I. Patient characteristics (N ¼ 15). Data are give
Characteristic
Sex Male/fe
Age, median (range), y 57 (49–
ECOG performance status 0
1
Histopathologic diagnosis Adenoc
Squam
Large c
NSCLC
Stage IIIB
IV
ECOG ¼ Eastern Cooperative Oncology Group; NSCLC ¼ non–
February 2016Peripheral neuropathy tended to worsen with the
number of infusions. Higher doses were associated with
earlier-onset and more severe peripheral neuropathy.
Three patients, including 1 patient at level 2 and 2
patients at level 3, required omission of treatment
during a cycle because of peripheral neuropathy. Apart
from alopecia and peripheral neuropathy, routine treat-
ment either resolved or mitigated most toxicities.
The most common hematologic and biochemical
abnormalities were decreased red blood cell count
(100%), hemoglobin (100%), and hematocrit (100%),
followed by leukopenia (86.7%), neutropenia (66.7%),
decreased serum albumin (66.7%), and elevated
C-reactive protein (66.7%). Grade 3 leukopenia, neu-
tropenia, and lymphocytopenia occurred in 13.3% of
patients; all had received level 3 paclitaxel. All lympho-
cytopenias occurred in patients with grade 2 lympho-
cytopenia before paclitaxel treatment.
The MTD was not determined because no DLT
occurred. DSMC identiﬁed hematologic toxicities of
grade Z3 and peripheral neuropathy that was asso-
ciated with treatment discontinuation as DLTs. The
maximum accepted dose was determined as level 3
because peripheral neuropathy necessitated treatment
discontinuation during a treatment cycle in 4 of 6
patients in the level 3 cohort.Antitumor Activity
Of the 15 patients, 3 achieved a partial response,
including 2 (of 6) at level 2 and 1 (of 6) at level 3. Then as number of patients unless otherwise specified.
n
male 15/0
69) 15
4
11
arcinoma 9
ous cell carcinoma 2
ell carcinoma 1
, not otherwise speciﬁed 3
3
12
small cell lung cancer.
341
Table II. Common toxicities during the first cycle.
Toxicity
80 mg/m2 (n ¼ 3) 100 mg/m2 (n ¼ 6) 120 mg/m2 (n ¼ 6) All Levels
G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
Fatigue 3 0 0 0 1 0 0 0 4 1 0 0 8 1 0 0
Anorexia 2 0 0 0 2 0 0 0 2 0 0 0 6 0 0 0
Arthralgia 1 0 0 0 2 0 0 0 3 0 0 0 6 0 0 0
Peripheral neuropathy 1 0 0 0 4 1 0 0 1 5 0 0 6 6 0 0
Alopecia 0 2 0 0 5 1 0 0 1 5 0 0 6 8 0 0
Decreased hemoglobin 3 0 0 0 5 1 0 0 5 1 0 0 13 2 0 0
Decreased hematocrit – – – – – – – – – – – – – – – –
Leukopenia 1 0 0 0 4 2 0 0 1 3 2 0 6 5 2 0
Neutropenia 0 0 0 0 2 2 0 0 1 3 2 0 3 5 2 0
Lymphocytopenia 0 0 0 0 0 3 0 0 0 2 2 0 0 5 2 0
Decreased serum albumin 3 – – – 3 – – – 4 – – – 10 – – –
Fasting hyperglycemia 2 0 0 0 1 1 0 0 0 0 0 0 3 1 0 0
G ¼ grade.
Clinical Therapeuticstime period for conﬁrmation of partial response
ranged from 37 to 45 days. Seven patients achieved
stable disease, and the overall response rate was
20.0%. Two patients showed progressive disease,
and 3 patients had disease that was not evaluable.Pharmacokinetics
The pharmacokinetics of paclitaxel at weeks 1 and
6 in the ﬁrst cycle are shown in Table III, and the
plasma concentration–time proﬁles are illustrated in
Figure 1. Cmax and AUC0–1 increased proportionally
with the increase in dose (Figure 2). Neither t½ nor Vss
exhibited dose dependency, but CLtot slightly
decreased. Pharmacokinetic parameters and plasma
paclitaxel concentration proﬁles were similar between
the ﬁrst and sixth infusions; the accumulation was not
signiﬁcant during repeated dosing.Plasma ACTH and Serum/Urinary Cortisol Levels
The administration of dexamethasone decreased
morning plasma ACTH and cortisol levels by 9 to
14 pg/mL and 1.0 to 2.0 mg/dL, respectively. A 2-week
dexamethasone-free interval was associated with lev-
els that were similar to those at baseline (Table IV).
Urinary 6β-OHC/C ratios after the ﬁrst and sixth
infusions were similar (Table V). The absence of a342change in the urinary 6β-OHC/C ratio suggested that
cytochrome P-450 (CYP) 3A4 was unaffected by the
administration of paclitaxel and dexamethasone.
Dexamethasone Taper and Hypersensitivity
Reactions
The prevalences of hypersensitivity reactions at
dexamethasone doses of 16, 8, 4, and 2 mg were
8.3% (1 event of 12 infusions), 20% (3 of 15), 20%
(3 of 15), and 14% (14 of 100), respectively. Dex-
amethasone dose reduction did not correlate with the
prevalence of hypersensitivity reactions. In the group
of 3 patients who received dexamethasone at 1 mg,
none experienced a hypersensitivity reaction (0 events
in 27 infusions). The hypersensitivity reactions were
grade r2 and included hypotension, ﬂushing, rash,
malaise, and sinus bradycardia. The prevalence of
hypersensitivity reaction did not correlate with the
paclitaxel dose.DISCUSSION
The present Phase I study was conducted to examine
the tolerability and pharmacokinetics of weekly pacli-
taxel in Japanese patients with advanced NSCLC, and
the feasibility of dexamethasone taper for the premed-
ication regimen. Our ﬁndings showed that no DLTVolume 38 Number 2
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Table III. Pharmacokinetic parameters. Data are given as mean (SD).
Dose
(mg/m2) Infusion
Cmax AUC0–1 AUClast t½ MRT0–1 CLtot Vss
Rac(μg/mL) P (μg ∙ h/mL) P (μg ∙ h/mL) P (h) P (h) P
(mL/min/
m2) P
(mL/min/
body) (L/m2) (L/body) P
80 (n ¼ 3) Week 1 3.907
(0.383)
0.8756 5.446
(0.451)
0.9239 5.016
(0.390)
0.9746 11.6
(1.3)
0.6168 5.7
(1.3)
0.5674 246.0
(20.7)
0.9888 424.7
(61.8)
83.7
(17.1)
143.7
(27.8)
0.6565 1.03
(0.22)
Week 6 4.061
(0.955)
5.639
(1.479)
5.156
(1.422)
12.2
(1.5)
6.2
(0.8)
246.5
(58.2)
426.1
(110.8)
93.7
(31.8)
161.6
(55.8)
100 (n ¼ 6) Week 1 5.933
(0.760)
0.9177 8.132
(1.544)
0.8470 7.672
(1.484)
0.9145 8.5
(2.4)
0.0208 4.1
(1.1)
0.0485 211.5
(41.6)
0.9007 356.7
(82.2)
50.0
(9.3)
84.0
(17.0)
0.0067 1.03
(0.13)
Week 6 5.904
(0.945)
8.452
(2.291)
7.899
(2.246)
12.0
(1.9)
5.9
(1.6)
208.1
(49.1)
350.4
(85.2)
71.0
(11.9)
118.4
(15.8)
120 (n ¼ 6) Week 1 7.227
(0.898)
0.0363 10.543
(1.056)
0.0600 10.119
(0.931)
0.0386 8.8
(2.8)
0.1662 4.6
(1.9)
0.2669 191.2
(17.7)
0.0618 312.7
(31.7)
52.4
(20.3)
86.4
(36.7)
0.0961 0.89
(0.06)
(n ¼ 5) Week 6 6.043
(0.549)
9.059
(0.983)
8.563
(0.981)
12.4
(4.2)
6.3
(2.3)
222.9
(24.1)
363.7
(47.8)
83.0
(26.0)
137.3
(49.5)
*P values estimated by ANOVA for week 1 versus week 6.
CLtot ¼ total clearance; MRT0–1 ¼ mean residence time; Rac ¼ accumulation ratio; Vss ¼ volume of distribution at steady state.
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the first infusion versus dose.
Clinical Therapeutics35%,16 respectively. These prevalences of grade 3/4
neutropenia are comparable to that (39%) seen in
non-Japanese patients with advanced NSCLC who
received weekly paclitaxel at 150 mg/m2.6 Other
notable hematologic toxicities in the present studyTable IV. Changes in plasma ACTH and cortisol. S
administration. Data are given as mean (SD)
Cycle Week n Plasma
1 1 15 6
2 15 4
3 15 4
4 15 4
5 15 5
6 15 4
2 1 11 7
ACTH ¼ adrenocorticotropic hormone.
344included anemia (100%; grade 3/4, 0%) and
leukopenia (86.7%; grade 3/4, 20%), which are
well-documented adverse effects of paclitaxel therapy.
All nonhematologic adverse effects, apart from alope-
cia and peripheral neuropathy, either resolved or were
mitigated with routine treatment. In the present study,
peripheral neuropathy was relatively common (80%),
but no cases were grade 3 or 4. Omission of paclitaxel
during the cycle was required in 3 patients, whereas
others had symptoms that were managed for 2 to 3
cycles (12–18 infusions).
Dexamethasone taper was conducted to reduce the
likelihood of glucocorticoid-related adverse events in
patients receiving weekly dexamethasone premedica-
tion before paclitaxel infusions. Adverse effects of
excess glucocorticoid included Cushing syndrome
(grade 1) in the fourth cycle (1 patient) and fasting
hyperglycemia (7 patients; 5 patients with grade 1,
and 2 patients with grade 2) between the ﬁrst and
fourth cycles. Dexamethasone dose reduction did not
correlate with the prevalence of hypersensitivity reac-
tion, and no severe hypersensitivity reactions occurred
(all were grader2). These observations are consistent
with the lack of increase in the prevalence of signiﬁ-
cant hypersensitivity reactions in studies of lowered
dexamethasone dose (10 mg) in patients on weekly
paclitaxel regimens.21,27 A recent report by Berger et al17
described an absence of hypersensitivity reactions
in 55 breast cancer patients whose dexamethasone
premedication was ceased after uneventful ﬁrst and
second doses of paclitaxel, including 31 patients on
weekly paclitaxel at 80 mg/m2. To our knowledge, noamples were taken immediately before paclitaxel
.
ACTH (pg/mL) Plasma Cortisol (μg/dL)
1.8 (23.1) 17.01 (4.59)
8.2 (17.8) 15.97 (5.16)
8.5 (23.8) 15.49 (3.30)
7.8 (18.1) 15.09 (3.40)
2.8 (22.3) 15.70 (3.06)
8.3 (18.9) 15.94 (3.90)
1.2 (30.6) 16.60 (3.34)
Volume 38 Number 2
Table V. Urinary 6β-hydroxycortisol/cortisol ratio (OHC/C). Data are given as mean (SD).
Timing of Urine Sampling n 6β-OHC/C
First cycle Week 1 15 6.999 (2.621)
Week 3 15 7.552 (3.095)
Week 4 15 7.565 (2.900)
Week 6 15 6.978 (2.073)
Before start of second cycle 11 7.344 (2.675)
H. Nokihara et al.study has attempted dexamethasone taper in Japanese
NSCLC patients on a weekly paclitaxel regimen.
In the present study, plasma ACTH and serum/
urinary cortisol were measured to examine the
possible effect of dexamethasone premedication on
adrenocortical function. Results showed that the
administration of dexamethasone decreased morning
plasma ACTH and cortisol levels by 9 to 14 pg/mL
and 1.0 to 2.0 mg/dL, respectively, but levels ap-
proached those seen at baseline after a 2-week
dexamethasone-free interval. No clear trend was
observed in other static tests of adrenocortical
function.
CYP3A4 is involved in the metabolism of pacli-
taxel, and its induction by paclitaxel has been dem-
onstrated in vitro.30 In the present study, urinary
6β-OHC/C ratios were determined to monitor
paclitaxel-induced changes in CYP3A4 activity. The
absence of a change in the urinary 6β-OHC/C ratio
suggested that CYP3A4 was unaffected by the admin-
istration of paclitaxel and dexamethasone. This ﬁnd-
ing was consistent with the lack of correlation
between plasma paclitaxel concentration and urinary
6β-OHC/C ratio in a study of patients with metastatic
breast cancer on weekly paclitaxel.31
As listed in Table III, the PK characteristics at each
dose of the 1-hour infusion in the present study were
similar to those observed with a previous 3-hour
infusion of 105 to 135 mg/m2 of paclitaxel.32
Several study limitations warrant mention. The
number of patients was small, and examination in a
larger number of patients is needed. In particular, the
reported rate21 of severe hypersensitivity reactions due
to paclitaxel is small (2%), so the patient number in
the present study was inadequate to observe a change
in the prevalence of hypersensitivity reaction after
dexamethasone taper. Second, only static tests ofFebruary 2016adrenocortical function were performed, and
dynamic testing, speciﬁcally an ACTH stimulation
test, is required to accurately assess adrenocortical
function.CONCLUSIONS
Weekly infusions of paclitaxel at 100 mg/m2 over
1 hour were well tolerated when administered in
6-week-long cycles followed by a 2-week treatment-
free interval. Dexamethasone taper was found to be
feasible for this weekly paclitaxel regimen and war-
rants further investigation. To our knowledge, this is
the ﬁrst study to evaluate weekly paclitaxel admin-
istration and the feasibility of dexamethasone tapering
in Japanese patients with advanced NSCLC.ACKNOWLEDGMENTS
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